PT-141 / Bremelanotide: FDA-Drug-Approved Sexual Health Peptide and Off-Label Use

Most peptides in this space have zero human trials. PT-141 has the opposite problem: it cleared a full Phase III programme, got FDA approval, and is sold under a brand name. The catch is what it was approved for. Bremelanotide (Vyleesi) is approved to treat low sexual desire in premenopausal women. Almost everyone in the performance world taking it is a man using it off-label for something else entirely. That gap is the story.

What PT-141 is

PT-141 is a cyclic seven-amino-acid peptide that switches on melanocortin receptors, mostly the melanocortin 4 receptor (MC4R). It came out of melanotan II, an earlier melanocortin compound studied for tanning and sexual function.

The mechanism is the genuinely interesting part. Viagra and Cialis (PDE5 inhibitors) work on blood vessels in the periphery: more blood flow, plumbing-level. PT-141 works in the brain. It acts on desire pathways in the hypothalamus and limbic system, not on circulation. Different lever entirely. That’s why it gets attention from people for whom the blood-flow drugs don’t work or aren’t safe. Whether a different lever produces a better outcome in those people is a separate question the trials weren’t built to answer.

The Phase III dataset

This is where PT-141 separates itself. It has a real Phase III dataset, the RECONNECT trials. A 2019 paper in Obstetrics and Gynecology by Kingsberg and colleagues reported the combined results: two identical randomised, double-blind, placebo-controlled trials in premenopausal women with hypoactive sexual desire disorder (HSDD). The endpoints were a desire subscale of the Female Sexual Function Index and the Female Sexual Distress Scale. Both trials showed statistically significant improvements in desire and drops in distress versus placebo, at the study dose, injected under the skin.

Statistically significant isn’t the same as large. The effect was moderate. The FDA weighed that against a side-effect profile reported in a companion long-term safety study by Simon and colleagues: nausea in roughly 40% of subjects, flushing, and transient blood pressure rises. The approved label recommends against use in people with cardiovascular disease and flags the blood pressure point. A drug clearing approval with a warning that prominent tells you the regulator thought hard about the trade.

The central MC4R mechanism is the basis for both the desire effect and the side-effect profile — central rather than vascular action.

Approved drug, off-label use, compounding limits

PT-141 needs the approved-versus-off-label line drawn cleanly, because the legal picture turns on it.

The approved drug: bremelanotide, sold as Vyleesi (originally AMAG Pharmaceuticals, now Palatin Technologies), got FDA drug approval in June 2019 under NDA 210557 for HSDD in premenopausal women. State that plainly: this peptide is an approved drug for one specific, narrow indication, backed by Phase III evidence. That’s Level 1. No hedging needed.

The off-label use: the men taking PT-141 for erectile dysfunction or general sexual function are using it outside the approved indication, in a population the pivotal trials never enrolled. Off-label prescribing is legal for a licensed physician. It just isn’t backed by the evidence that earned the approval. The approval is for women with HSDD. The community using it mostly isn’t that.

Compounding: because bremelanotide is the active ingredient in an approved drug, FDA compounding rules restrict making what amounts to a copy of a commercially available approved product. That’s the same constraint tesamorelin faces. The legal position for compounded PT-141 is messy, and operations selling it have drawn regulatory attention.

One thing PT-141 isn’t: it’s not on the PCAC July 23–24, 2026 docket — the Federal Register notice listing nominated bulk substances doesn’t include it. It’s governed by existing drug law, not the bulk-substances compounding pathway that catches the unapproved peptides.

Where the data thins

The Phase III HSDD data is the strongest evidence point in this whole series. The gaps sit outside that approved box.

Efficacy in men isn’t established by controlled trials. The male sexual-function interest, which is what drives most of the demand, has no Phase III equivalent to RECONNECT behind it. Some smaller exploratory work exists. It doesn’t carry the same weight, and pretending otherwise would be the easy lie.

Long-term cardiovascular safety isn’t characterised. The transient blood pressure rise, plus the cardiovascular contraindication on the label, means the chronic-use picture, especially for off-label users without HSDD, hasn’t been mapped.

The desensitisation question is open. Whether chronic MC4R stimulation downregulates the receptor or fades over time hasn’t been reported in long-term human studies. Nobody knows.

The PT-141 verdict

PT-141 is the rare peptide where the science isn’t the weak point: there’s genuine Phase III evidence behind a real FDA approval. The weak point is the mismatch. The approval covers low desire in premenopausal women. Most of the people using it are men, off-label, for something the trials never tested. The compounding restriction, parallel to tesamorelin’s, adds legal friction on top.

The honest framing: the approved-indication data is solid, the off-label extrapolation is a long way past it, and that distinction is the entire thing worth understanding here.